(Q47409968)

English

LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia

scientific article published on 13 October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

1

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

2

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

4

object named as

Gabor Halmos

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

3

object named as

Norman L Block

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

Irving Vidaurre

7

object named as

Irving Vidaurre

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

8

object named as

Luca Szalontay

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

author name string

Roberto Perez

5

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

Jesus B Fernandez

6

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

publication date

13 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

71

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

7

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

736-747

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the Comb

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Molecular and cellular pathogenesis of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Benign prostatic hyperplasia: age-related tissue-remodeling

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Growth factors in benign prostatic hyperplasia: basic science implications

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Regulation of prostatic growth and function by peptide growth factors

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

New approaches to the therapy of various tumors based on peptide analogues

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Steroid abuse in athletes, prostatic enlargement and bladder outflow obstruction--is there a relationship?

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Influence of hormone treatment on prostate growth and micturition characteristics of the rat.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: focus on detrusor overactivity.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

A new mathematical model for relative quantification in real-time RT-PCR

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

GnRH antagonists in the treatment of gynecological and breast cancers

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Asymptomatic inflammation and/or infection in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21289

21 January 2018

Role of chronic inflammation in the promotion of prostatic hyperplasia in rats

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21289

Infravesical outflow obstruction in rats: a comparison of two models

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21289

Testosterone-induced prostatic growth in the rat causes bladder overactivity unrelated to detrusor hypertrophy

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21289

Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21289

High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21289

New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21289

Prostatic ductal system in rats: regional variation in stromal organization

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21289

Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21289

Distribution of Inflammation, Pre-Malignant Lesions, Incidental Carcinoma in Histologically Confirmed Benign Prostatic Hyperplasia: A Retrospective Analysis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21289

Identifiers

10.1002/PROS.21289

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/20945403

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47409968&oldid=2201989829"